S
Satoshi Shiba
Researcher at Juntendo University
Publications - 26
Citations - 1957
Satoshi Shiba is an academic researcher from Juntendo University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 9, co-authored 19 publications receiving 956 citations.
Papers
More filters
Journal ArticleDOI
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Shun Yamamoto,Ken Kato,Hiroyuki Daiko,Takashi Kojima,Hiroki Hara,Tetsuya Abe,Yasuhiro Tsubosa,Kengo Nagashima,Kazunori Aoki,Yukihiro Mizoguchi,Shigehisa Kitano,Shinichi Yachida,Satoshi Shiba,Yuko Kitagawa +13 more
TL;DR: The safety and efficacy of nivolumab adding to neoadjuvant chemotherapy for ESCC is unknown and the primary end point is the incidence of dose-limiting toxicities from the initial dose to the 30th postoperative day.
Journal ArticleDOI
Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study.
Satoshi Shiba,Hiroshi Imaoka,Kazuhiko Shioji,Eiichiro Suzuki,Shigeru Horiguchi,Takeshi Terashima,Yasushi Kojima,Tatsuya Okuno,Yasutaka Sukawa,Kunihiko Tsuji,Kumiko Umemoto,Akinori Asagi,Akiko Todaka,Makoto Ueno,Masafumi Ikeda,Chigusa Morizane,Junji Furuse +16 more
TL;DR: Tumor size > 3.0 cm is an independent indicator of a poor prognosis in epithelioid hemangioendothelioma, and the presence of symptoms at the time of diagnosis and high Ki-67 index implied poor survival.
Journal ArticleDOI
Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients
Satoshi Shiba,Chigusa Morizane,Nobuyoshi Hiraoka,Mitsuhito Sasaki,Futa Koga,Yasunari Sakamoto,Shunsuke Kondo,Hideki Ueno,Masafumi Ikeda,Tesshi Yamada,Kazuaki Shimada,T Kosuge,Takuji Okusaka +12 more
TL;DR: Staging classification and the WHO 2010 grading are important factors for selecting the appropriate treatment strategy and predicting prognosis for patients with pancreatic NEN.
Journal ArticleDOI
Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib.
TL;DR: Sorafenib, a multi‐targeted tyrosine kinase inhibitor, is a first‐line systemic treatment for advanced hepatocellular carcinoma (HCC) and possible predictors of the efficacy of sorafenIB treatment in HCC patients remain unclear.
Journal ArticleDOI
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.
Shun Yamamoto,Ken Kato,Hiroyuki Daiko,Takashi Kojima,Hiroki Hara,Tetsuya Abe,Yasuhiro Tsubosa,Hirofumi Kawakubo,Takeo Fujita,Takashi Fukuda,Shigenori Kadowaki,Takahiro Tsushima,Yasuo Hamamoto,Kengo Nagashima,Kazunori Aoki,Yukihiro Mizoguchi,Shigehisa Kitano,Shinichi Yachida,Satoshi Shiba,Yuko Kitagawa +19 more
TL;DR: The standard neoadjuvant chemotherapy in Japan for locally advanced esophageal squamous cell cancer is CDDP + 5-FU (CF).